Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABT

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Benzinga

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Barchart

‘She redefined who belongs’: Misty Copeland takes final bow with American Ballet Theatre

Copeland made history as the first Black female principal dancer in the company's 75-year existence

The Independent UK

Miss Panama Isamar Herrera Embraces Newfound Fame After Miss Grand International 2025 Blunder

Miss Panama Isamar Herrera experienced an embarrassing moment during the Miss Grand International 2025. But, she's now embracing her newfound popularity.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Why Did Misty Copeland Quit ABT? Principal Exits ABT With No Successor in Sight—Is Ballet Still Not Ready for Black Ballerinas?

Misty Copeland ends her 25-year journey with American Ballet Theatre, questioning ballet's slow progress on diversity as no Black successor follows.

International Business Times UK

Misty Copeland will take to the ballet stage one last time, before hanging up her pointe shoes

Misty Copeland is taking one last passionate spin on the ballet stage before saying goodbye

The Independent UK

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

Barchart

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

MarketBeat

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

Benzinga

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Abbott Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.

Barchart

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks?

Although Abbott Laboratories has underperformed its industry peers recently, analysts remain highly optimistic about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Latin Times

Latino Dancer Isaac Hernández Dazzles New York in 'Swan Lake' Debut with American Ballet Theatre: Celebrated with Birria Tacos

Mexican-born ballet sensation Isaac Hernández made headlines this weekend in New York City, taking center stage at the Metropolitan Opera House as Prince Siegfried in Swan Lake. Performing as part of American Ballet Theatre's 2025 summer season,

The Independent UK

What does one do on their last day as a ballerina? Gillian Murphy will jump off a cliff (gracefully)

After a career of nearly three decades, Gillian Murphy is hanging up her pointe shoes

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.

Benzinga

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.

Benzinga

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the second quarter, before the opening bell on Thursday, July 17.

Barchart

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.